Publications by authors named "Bruce Lyday"
Article Synopsis
- Recent research is shifting cancer treatment focus from direct viral effects to immune activation, utilizing oncotropic viruses like PV001-DV, a safe strain of Dengue virus known for its immune-boosting properties.
- The study demonstrated PV001-DV's ability to directly kill melanoma cells and enhance immune responses in patient blood cells, showing promising results in tumor cell death.
- These findings support further clinical trials of PV001-DV in advanced melanoma patients who have not responded to other treatments.
Combining dendritic cell vaccination with the adjuvant effect of a strain of dengue virus may be a way to overcome known tumor immune evasion mechanisms. Dengue is unique among viruses as primary infections carry lower mortality than the common cold, but secondary infections carry significant risk of hypovolemic shock. While current immuno-therapies rely on a single axis of attack, this approach combines physiological (hyperthermic reduction of tumor perfusion), immunological (activation of effector cells of the adaptive and innate immune system), and apoptosis-inducing pathways (sTRAIL) to destroy tumor cells.
View Article and Find Full Text PDF